Skip to main content

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

November 2015 - FRMC

12/16/2015
The introduction of biosimilars could mean reductions in health care costs; however, education and preparation will be required for their successful use.
The introduction of biosimilars could mean reductions in health care costs; however, education and preparation will be required for their successful use.
The introduction of biosimilars...
12/16/2015
First Report Managed Care
12/16/2015
Determining the vale of a drug may require less data than you realize
Determining the vale of a drug may require less data than you realize
Determining the vale of a drug...
12/16/2015
First Report Managed Care
12/16/2015
NULL
NULL
 The status of orphan drug develop­ment in 2 rare disease states—as well as key manage­ment strategies—were addressed by 2 experts during AMCP Nexus 2015. Rare diseases are exceptionally diverse. “The only thing in common [between] them is...
 The status of orphan drug develop­ment in 2 rare disease states—as well as key manage­ment strategies—were addressed by 2 experts during AMCP Nexus 2015. Rare diseases are exceptionally diverse. “The only thing in common [between] them is...
 The status of orphan drug...
12/16/2015
First Report Managed Care
12/16/2015
Specialty Pharma: The Good, the Bad, and the Challenging The rising cost of specialty pharmaceuticals is a critical issue among managed care professionals.  
Specialty Pharma: The Good, the Bad, and the Challenging The rising cost of specialty pharmaceuticals is a critical issue among managed care professionals.  
Specialty Pharma: The Good, the...
12/16/2015
First Report Managed Care

Advertisement

Advertisement

Advertisement